Enliven Therapeutics SEC filings document a clinical-stage biopharmaceutical issuer developing small-molecule therapeutics, with disclosures centered on ELVN-001 for chronic myeloid leukemia and related operating results and cash resources. Current reports furnish quarterly and annual financial results and attach business updates describing ENABLE clinical-trial activity, regulatory-development topics, and program plans.
Proxy and governance filings describe annual meeting matters, board composition, committee leadership, executive transitions, director compensation, equity awards, and stockholder voting procedures. The filings also identify Enliven common stock on the Nasdaq Global Select Market and record material-event amendments when furnished press-release exhibits are corrected.
Director J. Scott Garland exercised options covering 13,000 ELVN shares on October 1, 2026, at an exercise price of $15.47 per share, acquired 13,000 common shares, and sold 13,000 shares at a weighted average $46.6707 per share. The reported sale prices ranged from $46.62 to $46.87 per share. The reported option position was 46,372 shares following the exercise. No Rule 10b5-1 plan is reported.
Enliven Therapeutics, Inc. (ELVN) is the issuer named in a Rule 144 notice listing director Jeffrey Garland as the seller; the notice is signed Jeffrey Scott Garland. It covers a proposed sale of 13,000 common shares, with an aggregate market value of $606,719.10. Morgan Stanley Smith Barney LLC is listed as broker, and October 1, 2026 is the approximate sale date on NASDAQ. The notice also lists a stock option exercise from the issuer for 13,000 shares, with cash payment, dated October 1, 2026.
Enliven Therapeutics, Inc. (ELVN) reported that its chief financial officer, Benjamin Hohl, exercised stock options for 3,982 shares of Common Stock at an exercise price of $14.85 per share on September 17, 2026. The same day, he sold a total of 6,018 shares of Common Stock in multiple trades at weighted-average prices between about $50.03 and $51.49. Following the option exercise, he held 181,018 stock options from the original grant, and certain equity holdings are in the form of restricted stock units. All reported trades were effected under a Rule 10b5-1 trading plan adopted on March 18, 2026.
Enliven Therapeutics, Inc. (ELVN) reported that Chief Medical Officer Helen Louise Collins exercised stock options for 5,000 shares of Common Stock on September 17, 2026 at an exercise price of $2.48 per share and then sold 5,000 shares the same day in open-market transactions. The sales occurred in three tranches at weighted average prices of about $50.03, $50.71 and $51.48 per share, within ranges from $49.305 to $51.675, and were effected under a Rule 10b5-1 trading plan adopted on October 19, 2025. After the option exercise, Collins held 106,268 options that are fully vested and exercisable.
Enliven Therapeutics, Inc. (ELVN) received a notice under Rule 144 that officer Benjamin Hohl may sell up to 12,036 shares of common stock, with an aggregate market value of $591,208.32, through broker Jefferies LLC. The company reports 73,000,000 shares of common stock outstanding as of this notice.
The shares relate to 2,036 long shares from previously exercised options dated December 13, 2024 and 10,000 shares from a stock option exercise dated February 13, 2024. The notice also lists prior sales of 6,018 shares each month on June 17, July 17, and August 17, 2026, under the same arrangement.
All proposed and prior sales are stated to be made pursuant to a previously signed Rule 10b5-1 selling plan adopted on March 18, 2026, with representations regarding material non-public information made as of that adoption date.
Enliven Therapeutics, Inc. (ELVN) is the issuer for a planned resale of its common stock under Rule 144 by Richard A. Heyman, through a trust, with Fidelity Brokerage Services LLC acting as broker. The notice covers the proposed sale of 38,000 shares of common stock of Enliven.
The filing lists an aggregate market value of $2,252,830 for the shares to be sold and notes that Enliven had 60,904,946 shares outstanding of this class. The shares being sold originate from a prior stock option exercise for 15,418 shares and a restricted stock purchase agreement for 22,647 shares. The shares are held in the Richard A. Heyman and Anne E. Daigle Trust dated January 29, 2018, and are expected to be sold on the Nasdaq market.
Enliven Therapeutics, Inc. (ELVN) reported that its Chief Financial Officer, Benjamin Hohl, sold shares of the company’s Common Stock in two open-market transactions on August 17, 2026. He sold 4,630 shares at a weighted average price of $58.3517 per share and 1,388 shares at a weighted average price of $59.3536 per share, totaling 6,018 shares. The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on March 18, 2026. A portion of the securities associated with his holdings are restricted stock units (RSUs), each representing a contingent right to receive one share of Common Stock, subject to vesting conditions.
Enliven Therapeutics, Inc. (ELVN) reported that Chief Medical Officer Helen Louise Collins exercised a stock option for 5,000 shares of common stock at an exercise price of $2.48 per share and on the same date sold 5,000 shares in two open-market transactions at weighted average prices of $58.3717 and $59.3465. Following the option exercise, she held 111,268 option shares directly. These transactions were effected under a Rule 10b5-1 trading plan adopted on October 19, 2025.
Enliven Therapeutics, Inc. director Mika K. Derynck exercised stock options covering 158,795 shares of common stock on August 4, 2026 at exercise prices of $2.4800, $14.8500, $22.4700 and $25.2800 per share.
He then sold 158,795 shares at a weighted average price of $60.2134 per share, in multiple trades between $60.00 and $60.58, pursuant to a Rule 10b5-1 trading plan adopted on April 8, 2025. All options exercised were fully vested and exercisable.
Enliven Therapeutics Inc. is the subject of an amended Schedule 13G filing (Amendment No. 3) reporting a significant ownership position by institutional investor FMR LLC and Abigail P. Johnson. FMR LLC reports that it beneficially owns 10,713,540.41 shares of Enliven common stock, representing 15.0% of the class.
FMR LLC has sole voting power over 10,704,808 shares and sole dispositive power over 10,713,540.41 shares, with no shared voting or dispositive power. Abigail P. Johnson is reported as having sole dispositive power over the same 10,713,540.41 shares and a 15.0% beneficial ownership interest. One or more other persons may receive dividends or sale proceeds from these shares, but no such person holds more than five percent of the outstanding common stock.